Neuro: Meningioma: Free MSRA Podcast

⚕️ FREE MSRA PODCAST – Meningioma🎧 A clear, high-yield breakdown of this common CNS tumour arising from the meninges – perfect for exam prep and clinical scenarios.🧠 Key Learning Points📌 Definition• A primary brain tumour arising from meningothelial cells in the arachnoid mater• Typically benign, slow-growing, and extra-axial📌 Causes & Risk Factors• Genetic mutations – e.g. NF2, AKT1• Neurofibromatosis type 2• Female sex (2:1 ratio), age 40–70• Oestrogen exposure, radiation to head/neck, family history• Possible links: head trauma, breast cancer💡 Mnemonic: “NEURO Risk Factors” – NF2, Estrogen, Unknown genetics, Radiation, Older age📌 Pathophysiology• Tumours arise from arachnoid cap cells• Growth is mechanical, causing compression of local structures• 3 WHO grades:– Grade 1: Benign, slow-growing– Grade 2: Atypical, ↑ recurrence– Grade 3: Malignant, invasive, rare• Special types: Meningioma en plaque, Chordoid meningioma (linked to Castleman’s disease)📌 Symptoms• Headache, seizures, focal neurology (vision, weakness, sensory deficits)• Cognitive changes – e.g. disinhibition, memory loss• Raised ICP: vomiting, papilloedema, hydrocephalus• Location-specific:– Sellar region → panhypopituitarism– Spinal → Brown-Séquard syndrome💡 Mnemonic: HSNC – Headaches, Seizures, Neuro deficits, Cognitive changes📌 Differential Diagnosis• Other brain tumours: gliomas, schwannomas, metastases• Lymphoma, adenocarcinoma• Inflammatory: sarcoidosis• Infectious: tuberculosis• Essential: histopathology to confirm diagnosis📌 Diagnosis• MRI with contrast = gold standard• CT scan if MRI contraindicated• Angiography pre-op to assess vascularity• Histological biopsy confirms WHO grade• Markers: MIB1/Ki-67 (proliferation), progesterone receptors, somatostatin receptors (70%)📌 Management• Observation – for asymptomatic, slow-growing tumours• Surgical resection – mainstay, aim for total removal• Radiotherapy – for incomplete resection, recurrence, or high-grade lesions• Stereotactic radiosurgery – precise tumour targeting• Endovascular embolisation – reduce vascular supply pre-op or as palliative option• Chemotherapy/targeted therapy – limited role; under research• Steroids (dexamethasone) – reduce oedema/symptoms pre-op📌 Complications• Seizures, cognitive impairment, focal deficits• Tumour recurrence, especially in grades 2–3• Post-op complications – infection, bleeding• Radiation side effects, including delayed tissue injury📌 Prognosis• Excellent for Grade 1 with complete resection – ~80% 5-year survival• Poorer prognosis for Grade 3 – <60% 5-year survival• Recurrence rates higher with incomplete resection or higher grades• Long-term follow-up essential📎 More MSRA Resources for Meningioma📝 Revision Notes: https://www.passthemsra.com/topic/meningioma-revision-notes/🧠 Flashcards: https://www.passthemsra.com/topic/meningioma-flashcards/💬 Accordion Q&A Notes: https://www.passthemsra.com/topic/meningioma-accordion-qa-notes/🚀 Rapid Quiz: https://www.passthemsra.com/topic/meningioma-rapid-quiz/🧪 Quiz Bank: https://www.passthemsra.com/quizzes/meningioma/🎓 Full Course: https://www.passthemsra.com/courses/neurology-for-the-msra/Hashtags#MSRA #MSRARevision #MSRATextbook #MSRAQuiz #MSRAQuestionBank #MSRAFlashcards #MSRAQANotes #MSRAAccordions #MSRAOnlineRevision #MultiSpecialityRecruitmentAssessment #Meningioma #NeurologyForMSRA #BrainTumour #WHOGrading #NeuroOncology